SMNR Semnur Pharmaceuticals, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1913577 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY87.9%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,344.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,757.8%
Debt / equity—
Current ratio0.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-580.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $2.55M | $1.71M | — | — |
| SG&A expense | $157.87M | $2.98M | — | — |
| Operating income | -$160.42M | -$4.69M | -$3.17M | — |
| Interest expense | — | $96,242 | $36,909 | — |
| Pretax income | $0 | $0 | — | — |
| Income tax | $0 | $0 | — | — |
| Net income | -$160.42M | -$4.69M | $632,536 | -$419,390 |
| EBITDA | -$160.42M | -$4.69M | — | — |
| EPS (basic) | -0.78 | -0.02 | — | — |
| EPS (diluted) | -0.78 | -0.02 | — | — |
| Weighted avg. shares (diluted) | 204.78M | 200.00M | — | — |
| Banking | ||||
| Deposits | — | $75,292 | — | — |
| Balance sheet | ||||
| Cash & equivalents | $20,000 | $12,000 | $12,000 | $819,747 |
| Current assets | $596,000 | $6.00M | $209,440 | $907,836 |
| PP&E, net | $750,000 | $689,000 | — | — |
| Total assets | $1.35M | $6.68M | $50.69M | $86.28M |
| Current liabilities | $10.17M | $35,000 | $5.60M | $1.29M |
| Total liabilities | $22.10M | $49.47M | $8.49M | $4.18M |
| Shareholders' equity | -$20.75M | -$42.78M | -$38.09M | -$3.27M |
| Shares outstanding | 230.21M | 200.00M | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$5.87M | -$4.89M | -$632,783 | -$426,095 |
| Investing cash flow | — | $43.43M | $39.71M | -$84.15M |
| Financing cash flow | $5.88M | $4.89M | -$39.69M | $85.40M |
| Depreciation & amortization | $0 | $0 | — | — |
| Stock-based compensation | $142.44M | $660,000 | — | — |
| Share buybacks | — | $43.43M | $40.54M | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.